Curriculum Vitae

PERSONAL DETAILS

DR. AHMAD NAZRAN BIN FADZLI

  • Medical Lecturer

  • Department of Surgery
    Faculty of Medicine
  •    +603-79492441
  •   ahmadnazran@um.edu.my

ADMINISTRATIVE DUTIES
(Role),(Level),(Duration)
  • Coordinator, Faculty, 16/01/2019 to 31/12/2019
ACADEMIC QUALIFICATION
(Qualification),(Field),(Institution),(Year)
  • MSurg(UM)(2012), SURGERY, UNIVERSITI MALAYA (UM)
  • MBChB(2006), PERUBATAN DAN PEMBEDAHAN, UNIVERSITY OF LEICESTER, LEICESTER, UK
  • Expert Training, FARMASI KLINIKAL, UNIVERSITY OF LEICESTER, LEICESTER, UK
PUBLICATIONS
(Title of publication in APA style)
Refereed Journals
2019
  • Yii RSL et al., Predictive factors of prostate cancer diagnosis with PSA 4.0e10.0 ng/ml in a multi-ethnic Asian population, Malaysia, Asian Journal of Surgery, https://doi.org/10.1016/j.asjsur.2019.02.014 (WoS)
2015
  • NY Yap, R Rajandram, KL Ng, J Pailoor, A Fadzli, GC Gobe. Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms. Biomed Research International 2015 (2015), Article ID 476508, 22 pages. (WoS)
RESEARCH PROJECT
(Project title),(Role),(Duration),(Level)
Merck Sharp & Dohme (M) Sdn. Bhd
  • KEYNOTE-676 : Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676), Consultant, 2019 - 2024 (International)
  • International Funding
  • Robotic-a ssisted percutaneous access Interventional, non-randomized, open-label, non-comparative and First-in-Man Study, Consultant, 2018 - 2018 (International)
  • A Phase I V Interventional Safety, Efficacy and Quality of Life Study of ELIGARD in Prostate Cancer Patients in Asia (ELIGANT), Consultant, 2016 - 2019 (International)
  • A multi-centre, prospective, longitudinal registry of patients with prostate cancer in Asia, Consultant, 2015 - 2020 (International)
  • Sanofi-Aventis
  • SAVE-ONCO: A multinational, randomized, double- blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous throboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy , Coordinator, 2008 - 2008 (International)
  • SOCIAL RESPONSIBILITY ACTIVITIES
    (Contribution to Society),(Duration),(Level)
    • AWANI pagi: Bulan Kesedaran Kesihatan Lelaki Sedunia, 30/11/2019 to 30/11/2019
    PAPER PRESENTED
    (Title),(Event),(Date Presented),(Organiser),(Level)
    POSTER PRESENTER
  • metastatic RCC to contralateral ureter, Malaysian Urological COnference, 24/11/2016 to 27/11/2016, MUA (National)
  • Efficacy of Oral Chondroitin Sulphate (urosulf) in Reducing Ureteric Stent Related Symptoms, 14th Urological Association of Asia Congress 2016, 20/07/2016 to 24/07/2016, UAA & SUA (International)
  • Percutaneous Nephrolithotomy (PCNL) in a case of Horseshoe Kidney, 27th World Congress on Videourology & Clinical Urology, 09/06/2016 to 12/06/2016, Thai Urological Association (International)
  • Ultra-Mini Percutaneous Nephrolithotripsy: A UMMC Experience, Malaysian Urology Conference, 20/11/2015 to 22/11/2015, MUC (National)
  • Transrectal Ultrasound Guided Prostate Biopsy Complications - a UMMC experience, 23rd Malaysian Urological Conference, 21/11/2014 to 23/11/2014, Malaysian Urological Association (National)
  • Tubulocystic renal cell carcinoma presenting as spontaneous subcapsular haematoma, 22nd Malaysian Urological Conference, 22/11/2013 to 24/11/2013, Malaysian Urological Association (National)
  • PRESENTER
  • hair in urethra post scrotal skin hypospadias repair, Malaysian urological conference, 24/12/2017 to 26/12/2017, MUA (National)